109 related articles for article (PubMed ID: 1665350)
1. Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. The University of Texas M.D. Anderson Cancer Center.
Hum Gene Ther; 1991; 2(4):359-76. PubMed ID: 1665350
[No Abstract] [Full Text] [Related]
2. Molecular analysis of retroviral transduction in chronic myelogenous leukemia.
Claxton D; Suh SP; Filaccio M; Ellerson D; Gaozza E; Andersson B; Brenner M; Reading C; Feinberg A; Moen R
Hum Gene Ther; 1991; 2(4):317-21. PubMed ID: 1665348
[TBL] [Abstract][Full Text] [Related]
3. Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine.
Deisseroth AB; Kantarjian H; Talpaz M; Champlin R; Reading C; Andersson B; Claxton D
Hum Gene Ther; 1993 Feb; 4(1):71-85. PubMed ID: 8461383
[No Abstract] [Full Text] [Related]
4. Autografting in chronic myelogenous leukemia: new questions.
Carella AM; Frassoni F; Negrin RS
Leukemia; 1995 Mar; 9(3):365-9. PubMed ID: 7885034
[TBL] [Abstract][Full Text] [Related]
5. Selection of BCR/ABL-negative progenitor cells from chronic myeloid leukemia marrow.
Leemhuis T; Leibowitz D; Cox G; Srour EF; Tricot G; Hoffman R
Prog Clin Biol Res; 1992; 377():231-7. PubMed ID: 1279706
[No Abstract] [Full Text] [Related]
6. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
Deisseroth AB; Zu Z; Claxton D; Hanania EG; Fu S; Ellerson D; Goldberg L; Thomas M; Janicek K; Anderson WF
Blood; 1994 May; 83(10):3068-76. PubMed ID: 7514051
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission.
Brenner M; Krance R; Heslop HE; Santana V; Ihle J; Ribeiro R; Roberts WM; Mahmoud H; Boyett J; Moen RC
Hum Gene Ther; 1994 Apr; 5(4):481-99. PubMed ID: 8049305
[No Abstract] [Full Text] [Related]
8. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
9. [Chronic myeloid leukemia. New prospects for marrow autotransplantation].
Carella AM; Carlier P; Nati S; Congiu A; Pierluigi D; Raffo MR
Haematologica; 1991 Jun; 76 Suppl 3():337-51. PubMed ID: 1684348
[No Abstract] [Full Text] [Related]
10. A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of relapse/refractory neuroblastoma without apparent bone marrow involvement: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse.
Hum Gene Ther; 1991; 2(3):273-86. PubMed ID: 1661173
[No Abstract] [Full Text] [Related]
11. Use of autotransplants in chronic myeloid leukaemia.
Goldman JM; Deisseroth AB
Bone Marrow Transplant; 1992; 10 Suppl 1():74-6. PubMed ID: 1355687
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse.
Hum Gene Ther; 1991; 2(3):257-72. PubMed ID: 1661172
[No Abstract] [Full Text] [Related]
13. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Cottafavi L; Dotti GP; Rizzoli V
Bone Marrow Transplant; 1994 Sep; 14(3):425-32. PubMed ID: 7994267
[TBL] [Abstract][Full Text] [Related]
14. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
15. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
Yuan T; Zhou YQ; Herst CV; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
Prog Clin Biol Res; 1992; 377():227-30. PubMed ID: 1438419
[No Abstract] [Full Text] [Related]
16. Kinetics of hematopoiesis in bone marrow cultures from patients with chronic myeloid leukemia: effect of recombinant cytokines in dexter-type long-term cultures.
Luna-Bautista F; Sánchez-Valle E; Ayala-Sánchez M; Morales-Polanco M; Meillon-García L; Benítez-Bribiesca L; Mayani H
Hematology; 2003 Jun; 8(3):155-63. PubMed ID: 12745649
[TBL] [Abstract][Full Text] [Related]
17. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
Huang H; Chen Y; Chen W; Wu Y
Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
[TBL] [Abstract][Full Text] [Related]
18. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer.
Rill DR; Moen RC; Buschle M; Bartholomew C; Foreman NK; Mirro J; Krance RA; Ihle JN; Brenner MK
Blood; 1992 May; 79(10):2694-700. PubMed ID: 1316784
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow transplantation for leukemia.
Stuart RK
Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
[TBL] [Abstract][Full Text] [Related]
20. Clinical models of autotransplants in chronic myelogenous leukemia.
Butturini A; Gale RP
Leuk Lymphoma; 1993; 11 Suppl 1():255-7. PubMed ID: 8251906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
